📚 Biblioteca Científica CBD
Acesse estudos clínicos e ensaios randomizados sobre o uso medicinal do Canabidiol.
518+Artigos
103Condições
18Especialidades
2026Atualização
518 artigos encontrados
| Título | Ano | Condição | Nível de Evidência | DOI |
|---|---|---|---|---|
The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study | 2024 | Saudável | Nível I — RCT | DOI |
Comparison of Cannabis-Based Medicinal Product Formulations for Fibromyalgia: A Cohort Study | 2024 | Fibromialgia | Nível II — Coorte | DOI |
Therapeutic Potential of Topical Cannabis for the Treatment of Psoriasis: A Preliminary Clinical Evaluation of Two Different Formulation | 2024 | Psoríase | Nível I — RCT | DOI |
Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management | 2024 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
Influence of short-term chronic oral cannabidiol application on muscle recovery and performance after an intensive training protocol - a randomized double-blind crossover study | 2024 | Saudável | Nível I — RCT | DOI |
Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis | 2024 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
The Effect of Cannabidiol on Subjective Responses to Endurance Exercise: A Randomised Controlled Trial | 2024 | Saudável | Nível I — RCT | DOI |
Is adjunctive Cannabidiol effective in controlling seizures for adult patients with Lennox-Gastaut Syndrome? – A single centre long term follow up study | 2024 | Epilepsia | Nível II — Coorte | DOI |
Cannabidiol for treatment of Irritability and Aggressive Behavior in Children and Adolescents with ASD: Background and Methods of the CAnnabidiol Study in Children with Autism Spectrum DisordEr (CASCADE) Study | 2024 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Topical nanoencapsulated cannabidiol cream as an innovative strategy combating UV-Aeinduced nuclear and mitochondrial DNA injury: A pilot randomized clinical study | 2024 | Eritema | Nível I — RCT | DOI |
Impact of Cannabidiol and Exercise on Clinical Outcomes and Gut Microbiota for Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors: A Case Report | 2024 | Câncer de Mama | Nível V — Série de Casos | DOI |
The Interplay of Exogenous Cannabinoid Use on Anandamide and 2-Arachidonoylglycerol in Anxiety: Results from a Quasi-Experimental Ad Libitum Study | 2024 | Ansiedade | Nível II — Coorte | DOI |
Cannabidiol for the Treatment of Cervical Spondyloarthritis-Related Pain: A Case Report | 2024 | Espondiloartrite Cervical | Nível V — Série de Casos | DOI |
Cannabidiol for behavior symptoms in Alzheimer’s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trial | 2024 | Doença de Alzheimer | Nível I — RCT | DOI |
The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial | 2024 | Insônia | Nível I — RCT | DOI |
Cannabidiol Compared to Pharmacological Treatment as Usual for Crack Use Disorder: A Feasibility, Preliminary Efficacy, Parallel, Double-Blind, Randomized Clinical Trial | 2024 | Dependência Química - Crack | Nível I — RCT | DOI |
Cannabidiol Intervention for Muscular Tension, Pain, and Sleep Bruxism Intensity—A Randomized, Double-Blind Clinical Trial | 2024 | Bruxismo | Nível I — RCT | DOI |
Limited Impact of Cannabidiol on Health-related Quality of Life of People With Long-term Controlled HIV: A Double-blind, Randomized, Controlled Trial | 2024 | HIV | Nível I — RCT | DOI |
Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer A Randomized Clinical Trial | 2024 | Câncer de Mama | Nível I — RCT | DOI |
Examination of the Effects of Cannabidiol on Menstrual-Related Symptoms | 2024 | Tensão Pré-Menstrual | Nível I — RCT | DOI |
Effects of Chronic Cannabidiol Dosing on Brain Blood Flow: Insights from the HYPER-H21-4 Trial | 2024 | Hipertensão | Nível I — RCT | DOI |
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: a randomized, double-blind, placebo-controlled trial | 2024 | Demência | Nível I — RCT | DOI |
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial | 2024 | COVID19 | Nível V — Série de Casos | DOI |
Effects of cannabidiol on symptoms in people at clinical high risk for psychosis | 2024 | Esquizofrenia | Nível I — RCT | DOI |
Purified cannabidiol as add-on therapy in children with treatment-resistant infantile epileptic spasms syndrome | 2024 | Epilepsia | Nível IV — Estudos transversais | DOI |
Effect of nabiximols oromucosal spray (Sativex) on symptoms associated with multiple sclerosis-related spasticity: a case series | 2024 | Esclerose Múltipla | Nível V — Série de Casos | DOI |
Effectiveness, Safety and Patients’ Satisfaction of Nabiximols (Sativex) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study | 2024 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Does cannabis affect cognitive functioning in patients with schizophrenia? | 2024 | Esquizofrenia | Nível IV — Estudos transversais | DOI |
Does Cannabidiol Treatment Provide an Effective Treatment for Anxiety and Depression in Older Adults in California? | 2024 | Ansiedade - Depressão | Nível IV — Estudos transversais | DOI |
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence | 2024 | Transtorno de Estresse Pós-Traumático | Nível IV — Estudos transversais | DOI |
Dose-dependent effects of oral cannabidiol and delta-9-tetrahydrocannabinol on serum anandamide and related N-acylethanolamines in healthy volunteers | 2024 | Saudável | Nível I — RCT | DOI |
The effects of a brand-specific, hemp-derived cannabidiol product on physiological, biochemical, and psychometric outcomes in healthy adults: a double-blind, randomized clinical trial | 2024 | Saudável | Nível I — RCT | DOI |
Short-term repeated oral intake of low dose cannabidiol: effects on liver enzyme activity and creatinine concentration during intense exercise | 2024 | Saudável | Nível I — RCT | DOI |
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study | 2024 | Saudável | Nível I — RCT | DOI |
Effect of Preoperative Oral Cannabidiol-Rich Cannabis Extract on Anxiety and Postoperative Pain after Endodontic Treatment: A Double-Blind Randomized Clinical Trial | 2024 | Dor - Dentista | Nível I — RCT | DOI |
Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomised Controlled Crossover Trial | 2024 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Cannabinoid levels description in a cohort of patients with chronic and neuropathic pain treated with Cannabis decoction: A possible role of TDM | 2024 | Dor Crônica | Nível II — Coorte | DOI |
Clinical outcome analysis of patients with multiple sclerosis – Analysis from the UK Medical Cannabis Registry | 2024 | Esclerose Múltipla | Nível V — Série de Casos | DOI |
Cannabidiol as an Alternative Analgesic for Acute Dental Pain | 2024 | Dor - Dentista | Nível I — RCT | DOI |
Acute effects of different types of cannabis on young adult and adolescent resting-state brain networks | 2024 | Saudável | Nível I — RCT | DOI |
UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia | 2024 | Insônia | Nível V — Série de Casos | DOI |
Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial | 2024 | Doença de Parkinson | Nível I — RCT | DOI |
An open‑label feasibility trial of transdermal cannabidiol for hand osteoarthritis | 2024 | Artrite | Nível IV — Estudos transversais | DOI |
UK medical cannabis registry: A clinical outcome analysis of medical cannabis therapy in chronic pain patients with and without co-morbid sleep impairment | 2024 | Dor Crônica | Nível V — Série de Casos | DOI |
A Preliminary Investigation of the Simultaneous Effects of Cannabidiol and Caffeine | 2024 | Saudável | Nível I — RCT | DOI |
Vaporized cannabis versus placebo for the acute treatment of migraine: a randomised, double-blind, placebo-controlled trial | 2024 | Enxaqueca | Nível I — RCT | DOI |
Medical Cannabis Prescription Practices and Quality of Life in Thai Patients: A Nationwide Prospective Observational Cohort Study | 2024 | Câncer | Nível II — Coorte | DOI |
Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at twelve NCI-Designated Cancer Centers | 2024 | Câncer | Nível IV — Estudos transversais | DOI |
Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry | 2024 | Osteoartrite | Nível IV — Estudos transversais | DOI |
Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial | 2024 | Dependência Química - Alcool | Nível I — RCT | DOI |
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial | 2024 | Câncer | Nível I — RCT | DOI |
Understanding the epidemiology and perceived efficacy of cannabis use in patients with chronic musculoskeletal pain | 2024 | Dor Crônica | Nível IV — Estudos transversais | DOI |
Serum Markers of Bone Turnover Following Controlled Administration of Two Medical Cannabis Products in Healthy Adults | 2024 | Saudável | Nível I — RCT | DOI |
A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of CBN With and Without CBD on Sleep Quality | 2024 | Insônia | Nível I — RCT | DOI |
A survey-based, quasi-experimental study assessing a high-cannabidiol suppository formenstrual-related pain and discomfort | 2024 | Tensão Pré-Menstrual | Nível III — Caso-Controle | DOI |
Medical Cannabis for Children with Autistic Spectrum Disorder: Is There a Difference Between Those Treated with Cannabis as Monotherapy vs Those Treated with Cannabis and Concomitant Conventional Medications? | 2024 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
Self-reported knowledge of tetrahydrocannabinol and cannabidiol concentration in cannabis products among cancer patients and survivors | 2024 | Câncer | Nível IV — Estudos transversais | DOI |
Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia | 2024 | Ansiedade | Nível V — Série de Casos | DOI |
A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis | 2024 | Esclerose Múltipla | Nível I — RCT | DOI |
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program | 2024 | Epilepsia - Esclerose tuberosa | Nível IV — Estudos transversais | DOI |
Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial | 2024 | Doença de Parkinson | Nível I — RCT | DOI |
Assessment of clinical outcomes in patients with inflammatory arthritis: analysis from the UK Medical Cannabis Registry | 2024 | Artrite | Nível V — Série de Casos | DOI |
A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood | 2024 | Saudável | Nível I — RCT | DOI |
Alterations to sphingolipid metabolism from antipsychotic administration in healthy volunteers are restored following the use of cannabidiol | 2024 | Saudável | Nível I — RCT | DOI |
A single dose of cannabidiol modulates the coupling between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis | 2024 | Episódio Psicótico | Nível I — RCT | DOI |
Final Analysis of Potential Drug-Drug Interactions between Highly Purified Cannabidiol (CBD) and Anti-Seizure Medications (ASMs) in an Open-Label Expanded Access Program | 2023 | Epilepsia | Nível II — Coorte | DOI |
Increased Hippocampal Blood Flow in People at Clinical High Risk for Psychosis and Effects of Cannabidiol | 2023 | Episódio Psicótico | Nível I — RCT | DOI |
Improved Post-Traumatic Stress Disorder Symptoms and Related Sleep Disturbances after Initiation of Medical Marijuana Use: Evidence from a Prospective Single Arm Pilot Study | 2023 | Transtorno de Estresse Pós-Traumático | Nível V — Série de Casos | DOI |
Medication sparing after medical cannabis initiation: A case study of a chronic pain patient in Project Twenty21 | 2023 | Dor Neuropática | Nível V — Série de Casos | DOI |
Myoclonic super-refractory status epilepticus with favourable evolution in a teenager with FIRES: Is the association of vagus nerve stimulation and cannabidiol effective? | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
Effects of cannabidiol on fear conditioning in anxiety disorders: decreased threat expectation during retention, but no enhanced fear re-extinction | 2023 | Ansiedade | Nível I — RCT | DOI |
Cannabis‑based magistral formulation is highly effective as an adjuvant treatment in drug‑resistant focal epilepsy in adult patients: an open‑label prospective cohort study | 2023 | Epilepsia | Nível II — Coorte | DOI |
Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study | 2023 | Esclerose Múltipla | Nível II — Coorte | DOI |
Oral capsules of tetra- hydro- cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment | 2023 | Dor Neuropática | Nível I — RCT | DOI |
Prevalence of Cannabidiol (CBD) consumption and cancer patients’ expectations in one Oncology Day Hospital: A cross-sectional study and questionnaire validation | 2023 | Câncer | Nível IV — Estudos transversais | DOI |
Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder | 2023 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial | 2023 | Úlceras Aftosas Recorrentes | Nível I — RCT | DOI |
Medical Marijuana for Pain Management in Hospice Care as a Complementary Approach to Scheduled Opioids: A Single Arm Study | 2023 | Dor | Nível V — Série de Casos | DOI |
Medical Cannabis for Chronic Posttraumatic Stress Disorder in Dutch Veterans: A Health Care Evaluation | 2023 | Transtorno de Estresse Pós-Traumático | Nível V — Série de Casos | DOI |
Oral Cannabidiol Treatment in Two Postmenopausal WomenwithOsteopenia: A Case Series | 2023 | Menopausa | Nível V — Série de Casos | DOI |
Management of Chronic Anal Fissure with a Novel Topical Hemp-Herbal-Based Ointment: A Pilot Study | 2023 | Fissura Anal | Nível II — Coorte | DOI |
Prevention of Taste Alterations in Patients with Cancer Receiving Paclitaxel- or Oxaliplatin-Based Chemotherapy — A Pilot Trial of Cannabidiol | 2023 | Câncer | Nível II — Coorte | DOI |
Mediators of Placebo Response to Cannabinoid Treatment in Children with Autism Spectrum Disorder | 2023 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial | 2023 | Esclerose Múltipla | Nível I — RCT | DOI |
Medical Cannabis Increases Appetite but Not Body Weight in Patients with Inflammatory Bowel Diseases | 2023 | Síndrome do Intestino Irritável | Nível V — Série de Casos | DOI |
Efficacy and usability of a cannabidiol-infused tampon for the relief of primary dysmenorrhea | 2023 | Dismenorreia | Nível I — RCT | DOI |
Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity | 2023 | Saudável | Nível I — RCT | DOI |
Effects of Oral Cannabidiol on Health and Fitness in Healthy Adults: An 8-Week Randomized Trial | 2023 | Saudável | Nível I — RCT | DOI |
Exploring The Effect Of 8 Weeks Of Cannabidiol On Serum Brain-Derived Neurotrophic Factor | 2023 | Saudável | Nível I — RCT | DOI |
High-purified cannabidiol efficacy and safety in a cohort of adult patients with various types of drug-resistant epilepsies | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center | 2023 | Epilepsia | Nível II — Coorte | DOI |
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures | 2023 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Examining the use of cannabidiol and delta-9-tetrahydrocannabinol-based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double-blind randomised crossover trial | 2023 | Demência | Nível I — RCT | DOI |
Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder | 2023 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Highly purified cannabidiol improves stability and postural tone in adult patients with Lennox– Gastaut syndrome: A case series | 2023 | Epilepsia - Síndrome de Lennox-Gastaut | Nível V — Série de Casos | DOI |
Cannabidiol (CBD) use among Canadian U Sport Student-Athletes:Patterns, Purposes, Benefits and Barriers of Use | 2023 | Saudável | Nível IV — Estudos transversais | DOI |
Cannabidiol in children with treatment-resistant epilepsy with myoclonic-atonic seizures | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study | 2023 | Saudável | Nível I — RCT | DOI |
Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state | 2023 | Esquizofrenia | Nível V — Série de Casos | DOI |
Cannabidiol in the acute phase of febrile infection- related epilepsy syndrome (FIRES) | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
Cannabidiol–drug interaction in cancer patients: A retrospective study in a real-life setting | 2023 | Câncer | Nível IV — Estudos transversais | DOI |
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS) | 2023 | Saudável | Nível I — RCT | DOI |
Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report | 2023 | Hipertensão Arterial Pulmonar | Nível V — Série de Casos | DOI |
Cannabidiol as an Adjunct to Botulinum Toxinin Blepharospasm – A Randomized Pilot Study | 2023 | Blefaroespasmo | Nível I — RCT | DOI |
A preliminary study evaluating self-reported effects of cannabis and cannabinoids on neuropathic pain and pain medication use in people with spinal cord injury | 2023 | Lesão da medula espinhal | Nível IV — Estudos transversais | DOI |
Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study | 2023 | Bipolaridade | Nível I — RCT | DOI |
A Randomized, Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis | 2023 | Gastroparesia | Nível I — RCT | DOI |
CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter,randomized, double-blind, placebo controlled, phase IIIb superiority study | 2023 | Síndrome de Tourette | Nível I — RCT | DOI |
Assessment of clinical outcomes in patientswith fibromyalgia: Analysis from the UK Medical Cannabis Registry | 2023 | Fibromialgia | Nível IV — Estudos transversais | DOI |
Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry | 2023 | Depressão | Nível IV — Estudos transversais | DOI |
A Semi‑Naturalistic, Open‑Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance | 2023 | Saudável | Nível V — Série de Casos | DOI |
An Updated Analysis of Clinical Outcome Measures Across Patients From the UK Medical Cannabis Registry | 2023 | Dor Crônica | Nível IV — Estudos transversais | DOI |
Antihypertensive effects of CBD are mediated by altered inflammatory response: A sub-study of the HYPER-H21-4 trial | 2023 | Hipertensão | Nível II — Coorte | DOI |
A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students | 2023 | Saudável | Nível I — RCT | DOI |
A Phase I Dose Escalation and Expansion Study of Epidiolex (Cannabidiol) in Patients with Biochemically Recurrent Prostate Cancer | 2023 | Câncer de Próstata | Nível II — Coorte | DOI |
A phase 2b randomised, placebo controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). | 2023 | Câncer | Nível I — RCT | DOI |
A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance | 2023 | Ansiedade | Nível IV — Estudos transversais | DOI |
Use of Cannabidiol in pediatric patients with refractory epilepsy of different etiologies | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial | 2023 | Esclerose Múltipla | Nível I — RCT | DOI |
Effects of CBD supplementation on ambulatory blood pressure and serum urotensin-II concentrations in Caucasian patients with essential hypertension: A sub-analysis of the HYPER-H21-4 trial | 2023 | Hipertensão | Nível I — RCT | DOI |
Effects of Oral Cannabinoids on Systemic Inflammation and Viral Reservoir Markers in People with HIV on Antiretroviral Therapy: Results of the CTN PT028 Pilot Clinical Trial | 2023 | HIV | Nível I — RCT | DOI |
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: a randomized, double-blind, placebo-controlled trial | 2023 | Demência | Nível I — RCT | DOI |
Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial | 2023 | Dependência Química - Opióides | Nível I — RCT | DOI |
Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk | 2023 | Episódio Psicótico | Nível I — RCT | DOI |
Efect of four‑week cannabidiol treatment on cognitive function: secondary outcomes from a randomised clinical trial for the treatment of cannabis use disorder | 2023 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Effect of Cannabidiol Oil on Post-ureteroscopy Pain for Urinary Calculi: A Randomized, Double-blind, Placebo-controlled Trial | 2023 | Dor Pós Cirúrgica | Nível I — RCT | DOI |
Does a broad‐spectrum cannabidiol supplement improve performance in a 10‐min cycle ergometer performance‐test? | 2023 | Saudável | Nível I — RCT | DOI |
Effect of CannEpil on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial | 2023 | Saudável | Nível I — RCT | DOI |
Does cannabidiol make cannabis safer? A randomised, double blind, cross-over trial of cannabis with four different CBD:THC ratios | 2023 | Saudável | Nível I — RCT | DOI |
Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study | 2023 | Hipertensão | Nível II — Coorte | DOI |
Effects of Two Cannabidiol Oil Products on Self-Reported Stress Relief: A Quasi-Experimental Study | 2023 | Ansiedade | Nível IV — Estudos transversais | DOI |
A Cross Sectional Comparison of the Mental Health, Sleep, and Anaerobic Power of Cannabis Users, Cannabidiol Users, and Non Users | 2023 | Saudável | Nível IV — Estudos transversais | DOI |
Chronic Effects of Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure in Patients with Hypertension (HYPER-H21-4): A Randomized, Placebo-Controlled, and Crossover Study | 2023 | Hipertensão | Nível I — RCT | DOI |
Concomitant cannabidiol does not impact safety and effectiveness of diazepam nasal spray for seizure clusters: Post hoc analysis of a phase 3 safety study | 2023 | Epilepsia | Nível II — Coorte | DOI |
Characterizing the Use of Nabiximols (∆9-Tetrahydrocannabinol–Cannabidiol) Buccal Spray in Pediatric Patients | 2023 | Dor | Nível V — Série de Casos | DOI |
Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey | 2023 | Epilepsia | Nível IV — Estudos transversais | DOI |
Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study | 2023 | Esclerose Múltipla | Nível I — RCT | DOI |
CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: A substudy from the HYPER-H21-4 trial | 2023 | Hipertensão | Nível I — RCT | DOI |
CBD-oil as a potential solution in case of severe tamoxifen-related side effects | 2023 | Câncer de Mama | Nível IV — Estudos transversais | DOI |
Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry | 2023 | Dor Crônica | Nível II — Coorte | DOI |
Comparing the effects of medical cannabis for chronic pain patients with and without co-morbid anxiety: A cohort study | 2023 | Dor Crônica | Nível IV — Estudos transversais | DOI |
The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment | 2023 | Saudável | Nível I — RCT | DOI |
Oral cannabidiol (CBD) as add-on to paracetamol for painful chronic osteoarthritis of the knee: arandomized,double-blind, placebo-controlled clinical trial | 2023 | Artrite | Nível I — RCT | DOI |
Perceptions and Prevalence of Cannabis Use in Women With Inflammatory Bowel Disease of Reproductive Age: A Cross-Sectional Study | 2023 | Síndrome do Intestino Irritável | Nível IV — Estudos transversais | DOI |
Safety and efficacy of orally administered full-spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in children with autism spectrum disorder: An open-label study | 2023 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
Relief of nocturnal neuropathic pain with the use of cannabis in a patient with Fabry disease | 2023 | Doença de Fabry | Nível V — Série de Casos | DOI |
Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome | 2023 | Epilepsia | Nível IV — Estudos transversais | DOI |
Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity | 2023 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Real-World Evidence of Factors Affecting Cannabidiol Exposure in Children with Drug-Resistant Developmental and Epileptic Encephalopathies | 2023 | Epilepsia | Nível IV — Estudos transversais | DOI |
Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex (cannabidiol) in patients with refractory epilepsy | 2023 | Epilepsia | Nível V — Série de Casos | DOI |
The effects of acute versus repeated cannabidiol administration on trauma-relevant emotional reactivity: A double-blind, randomized, placebo-controlled trial | 2023 | Transtorno de Estresse Pós-Traumático | Nível I — RCT | DOI |
The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial | 2023 | Saudável | Nível I — RCT | DOI |
The Effects of Long-Term Self-Dosing of Cannabidiol on Drowsiness, Testosterone Levels, and Liver Function | 2023 | Saudável | Nível III — Caso-Controle | DOI |
Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain | 2023 | Dor Crônica | Nível V — Série de Casos | DOI |
The Effects of Acute Cannabis With and Without Cannabidiol on Neural Reward Anticipation in Adults and Adolescents | 2023 | Saudável | Nível II — Coorte | DOI |
The Effects of Cannabidiol on the Driving Performance of Healthy Adults: A Pilot RCT | 2023 | Saudável | Nível I — RCT | DOI |
The Influence of Oral Cannabidiol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Untreated Hypertension: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study | 2023 | Hipertensão | Nível I — RCT | DOI |
The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder | 2023 | Episódio Psicótico | Nível I — RCT | DOI |
The holistic effects of medical cannabis compared to opioids on pain experience in Finnish patients with chronic pain | 2023 | Dor Crônica | Nível V — Série de Casos | DOI |
The effects of cannabidiol on worry and anxiety among high trait worriers: a double-blind, randomized placebo-controlled trial | 2023 | Ansiedade | Nível I — RCT | DOI |
The Effects Of Cannabidiol On Brain Temperature In Treatment resistant
Epilepsy | 2023 | Epilepsia | Nível III — Caso-Controle | DOI |
Severe and moderate autism spectrum disorder: serial cases treated with cannabidiol and tetrahydrocannabinol in a university hospital | 2023 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
The longitudinal effects of cannabidiol on brain temperature in patients with treatment-resistant epilepsy | 2023 | Epilepsia | Nível II — Coorte | DOI |
The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry | 2023 | Doença de Crohn | Nível V — Série de Casos | DOI |
Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study | 2023 | Hipertensão | Nível I — RCT | DOI |
UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention-deficit/hyperactivity disorder | 2023 | Transtorno de Déficit de Atenção e Hiperatividade | Nível V — Série de Casos | DOI |
UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders | 2023 | Enxaqueca | Nível V — Série de Casos | DOI |
Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial | 2023 | Epilepsia - Esclerose tuberosa | Nível I — RCT | DOI |
Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study | 2022 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
Effects of Cannabidiol and Δ-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study | 2022 | Saudável | Nível I — RCT | DOI |
Cannabis-Based Medicinal Products in the Management of Emotionally Unstable Personality Disorder (EUPD): A Narrative Review and Case Series | 2022 | Transtorno de Personalidade Borderline | Nível V — Série de Casos | DOI |
An Open Retrospective Study of a Standardized Cannabidiol Based-Oil in Treatment-Resistant Epilepsy | 2022 | Epilepsia | Nível IV — Estudos transversais | DOI |
Quantitative electroencephalographic analysis as a potential biomarker of response to treatment with cannabidiol | 2022 | Epilepsia | Nível III — Caso-Controle | DOI |
Electroencephalographic changes in purified pharmaceutical cannabidiol therapy | 2022 | Epilepsia | Nível III — Caso-Controle | DOI |
Prevalence of Cannabinoid (CBD) Use in Orthopaedic Sports Medicine Patients | 2022 | Saudável | Nível IV — Estudos transversais | DOI |
Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients | 2022 | Demência | Nível V — Série de Casos | DOI |
Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial | 2022 | Saudável | Nível I — RCT | DOI |
Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension (HYPER-H21-4): Study Protocol for a Randomized, Placebo-Controlled, and Crossover Study | 2022 | Hipertensão | Nível I — RCT | DOI |
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry | 2022 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program | 2022 | Epilepsia | Nível I — RCT | DOI |
Case report: Medical cannabis—warfarin drug-drug interaction | 2022 | AVC | Nível V — Série de Casos | DOI |
Medical Cannabis for Gilles de la Tourette Syndrome: An Open Label Prospective Study | 2022 | Síndrome de Tourette | Nível IV — Estudos transversais | DOI |
Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial | 2022 | Ansiedade | Nível I — RCT | DOI |
Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy | 2022 | Epilepsia | Nível II — Coorte | DOI |
Survey of local cannabidiol use in parents of children with epilepsy in Thailand: the prevalence, perceptions, and knowledge | 2022 | Epilepsia | Nível V — Série de Casos | DOI |
Neuropsychiatric Symptoms in Dementia. The Added Value of Cannabinoids. Are they a Safe and Effective Choice? Case Series with Cannabidiol 3% | 2022 | Doença de Alzheimer | Nível V — Série de Casos | DOI |
Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy | 2022 | Epilepsia | Nível IV — Estudos transversais | DOI |
UK Medical Cannabis registry: an analysis of clinical outcomes of medicinal cannabis therapy for chronic pain conditions | 2022 | Dor Crônica | Nível V — Série de Casos | DOI |
Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial | 2022 | Demência | Nível I — RCT | DOI |
Effects of Broad Spectrum Cannabidiol Oil on Behavioral Disturbances in Patients with Dementia: A Randomized Clinical Trial | 2022 | Demência | Nível I — RCT | DOI |
Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028) | 2022 | HIV | Nível I — RCT | DOI |
Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder | 2022 | Transtorno de Estresse Pós-Traumático | Nível I — RCT | DOI |
Patient Reported Outcomes of Medical Cannabis for Managing Pain in Charcot-Marie-Tooth Disease | 2022 | Charcot-Marie-Tooth | Nível IV — Estudos transversais | DOI |
Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology | 2022 | Câncer de Pele | Nível V — Série de Casos | DOI |
Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial | 2022 | Saudável | Nível I — RCT | DOI |
Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral Formulation | 2022 | Dor Crônica | Nível IV — Estudos transversais | DOI |
Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report | 2022 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
The Effectiveness and Safety of Medical Cannabis for Treating Cancer Related Symptoms in Oncology Patients | 2022 | Câncer | Nível IV — Estudos transversais | DOI |
UK Medical Cannabis Registry: an analysis of clinical outcomes of medicinal cannabis therapy for generalized anxiety disorder | 2022 | Ansiedade | Nível V — Série de Casos | DOI |
The effects of cannabidiol isolate on menstrual-related symptoms | 2022 | Tensão Pré-Menstrual | Nível II — Coorte | DOI |
An Open-Label Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE) | 2022 | Síndrome da deleção 22q11.2 | Nível V — Série de Casos | DOI |
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program | 2022 | Epilepsia | Nível II — Coorte | DOI |
Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study | 2022 | Transtorno de Estresse Pós-Traumático | Nível IV — Estudos transversais | DOI |
Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists | 2022 | Depressão | Nível IV — Estudos transversais | DOI |
Cannabis for the Treatment of Attention Deficit Hyperactivity Disorder: A Report of 3 Cases | 2022 | Transtorno de Déficit de Atenção e Hiperatividade | Nível V — Série de Casos | DOI |
Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters | 2022 | Saudável | Nível II — Coorte | DOI |
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy A Randomized Clinical Trial | 2022 | Epilepsia | Nível I — RCT | DOI |
A Single-Center Study Evaluating the Effects of a Novel Retinol and Cannabidiol Combination Topical on Facial Skin | 2022 | Saudável | Nível IV — Estudos transversais | DOI |
Acceptability of cannabidiol in patients with psychosis | 2022 | Episódio Psicótico | Nível IV — Estudos transversais | DOI |
Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study | 2022 | Dependência Química - Opióides | Nível IV — Estudos transversais | DOI |
Observational study of medical marijuana as a treatment for treatment-resistant epilepsies | 2022 | Epilepsia | Nível III — Caso-Controle | DOI |
A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described ‘spasticity-plus syndrome’ | 2022 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT‑FX) | 2022 | Síndrome do X Frágil | Nível I — RCT | DOI |
Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II) | 2022 | Dor | Nível I — RCT | DOI |
UK Medical Cannabis Registry palliative care patients cohort: initial experience and outcomes | 2022 | Câncer | Nível V — Série de Casos | DOI |
Cannabidiol Treatment for Neurological, Cognitive, and Psychiatric Symptoms in Sturge-Weber Syndrome | 2022 | Epilepsia - Síndrome de Sturge-Weber | Nível I — RCT | DOI |
Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry | 2022 | Transtorno de Estresse Pós-Traumático | Nível IV — Estudos transversais | DOI |
Buccally Absorbed Cannabidiol Shows Significantly Superior Pain Control and Improved Satisfaction Immediately After Arthroscopic Rotator Cuff Repair: A Placebo-Controlled, Double-Blinded, Randomized Trial | 2022 | Dor Pós Cirúrgica | Nível I — RCT | DOI |
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox–Gastaut syndrome (ELEKTRA) | 2022 | Epilepsia | Nível I — RCT | DOI |
Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study | 2022 | Insônia | Nível I — RCT | DOI |
A double‑blind, randomized, placebo‑controlled test of the effects of cannabidiol on fear elicited by a 10% carbon dioxide‑enriched air breathing challenge | 2022 | Saudável | Nível I — RCT | DOI |
Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study | 2022 | Artrite | Nível IV — Estudos transversais | DOI |
A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ | 2022 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial | 2022 | Ansiedade | Nível I — RCT | DOI |
Use of Medical Cannabis in Patients with Gilles de la Tourette’s Syndrome in a Real-World Setting | 2022 | Síndrome de Tourette | Nível IV — Estudos transversais | DOI |
A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Thumb Basal Joint Arthritis | 2022 | Artrite | Nível I — RCT | DOI |
The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event | 2022 | Transtorno de Estresse Pós-Traumático | Nível I — RCT | DOI |
Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety | 2022 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
Integration of Cannabis Extract Tetrahydrocannabinol:Cannabidiol in an Interdisciplinary Therapy Setting: A Case of Chronic Multilocular Pain Disorder | 2022 | Dor Crônica | Nível V — Série de Casos | DOI |
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6 | 2022 | Epilepsia - Esclerose tuberosa | Nível I — RCT | DOI |
Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in prospective, open-label clinical study with cannabidiol | 2021 | Epilepsia | Nível V — Série de Casos | DOI |
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity. | 2021 | Esclerose Múltipla | Nível II — Coorte | DOI |
Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial | 2021 | Dependência Química - Cocaína | Nível I — RCT | DOI |
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial | 2021 | Epilepsia - Síndrome de Dravet | Nível IV — Estudos transversais | DOI |
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients with Crohn’s Disease, a Randomised Controlled Trial | 2021 | Doença de Crohn | Nível I — RCT | DOI |
Cannabidiol (CBD) Use in Type 2 Diabetes: A Case Report | 2021 | Diabetes Tipo 2 | Nível V — Série de Casos | DOI |
A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor | 2021 | Tremor essencial | Nível I — RCT | DOI |
Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic A Randomized Clinical Trial | 2021 | Burn Out | Nível I — RCT | DOI |
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial | 2021 | Ansiedade - Depressão | Nível III — Caso-Controle | DOI |
Effects of Cannabidiol Supplementation on Skeletal Muscle Regeneration after Intensive Resistance Training | 2021 | Saudável | Nível IV — Estudos transversais | DOI |
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial | 2021 | Esquizofrenia | Nível I — RCT | DOI |
Cannabidiol modulation of hippocampal glutamate in early psychosis | 2021 | Episódio Psicótico | Nível I — RCT | DOI |
Assessing the effects of topical cannabidiol in patients with atopic dermatitis | 2021 | Eczema | Nível IV — Estudos transversais | DOI |
Cannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression | 2021 | Depressão | Nível V — Série de Casos | DOI |
Cannabis and cannabidiol use among autistic and non-autistic adults in the UK: a propensity score-matched analysis | 2021 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
Cannabidiol for the treatment of crack-cocaine craving: na exploratory double-blind study | 2021 | Dependência Química - Crack | Nível I — RCT | DOI |
Cannabinoid treatment for autism: a proof-of-concept randomized trial | 2021 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer’s Dementia | 2021 | Doença de Alzheimer | Nível V — Série de Casos | DOI |
Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder | 2021 | Doença de Parkinson | Nível I — RCT | DOI |
Prolonged Medical Cannabis Treatment is Associated With Quality of Life Improvement and Reduction of Analgesic Medication Consumption in Chronic Pain Patients | 2021 | Dor Crônica | Nível IV — Estudos transversais | DOI |
Clinical Outcome Data of First Cohort of Chronic Pain Patients Treated With Cannabis-Based Sublingual Oils in the United Kingdom: Analysis From the UK Medical Cannabis Registry | 2021 | Dor Crônica | Nível V — Série de Casos | DOI |
Cannabidiol-enriched medical cannabis as add-on therapy in children with treatment-resistant West syndrome: A study of eight patients | 2021 | Epilepsia - Síndrome de West | Nível V — Série de Casos | DOI |
Attitudes, beliefs, and changing trends of cannabidiol (CBD) oil use among caregivers of individuals with Alzheimer’s disease | 2021 | Doença de Alzheimer | Nível IV — Estudos transversais | DOI |
CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature | 2021 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
Cannabidiol use and effectiveness: real world evidence from a Canadian medical cannabis clinic | 2021 | Dor | Nível IV — Estudos transversais | DOI |
Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey | 2021 | Fibromialgia | Nível IV — Estudos transversais | DOI |
Caring for behavioral symptoms of dementia (CBD): A new investigation into cannabidiol for the treatment of anxiety and agitation in Alzheimer’s dementia | 2021 | Doença de Alzheimer | Nível V — Série de Casos | DOI |
Cannabis Use is Associated With Reduced 30-Day All-cause Readmission Among Hospitalized Patients With Irritable Bowel Syndrome | 2021 | Síndrome do Intestino Irritável | Nível II — Coorte | DOI |
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross‑sectional survey study | 2021 | Epidermólise Bolhosa | Nível IV — Estudos transversais | DOI |
Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series | 2021 | Dor - Câncer | Nível V — Série de Casos | DOI |
The Perception Of Cannabis Oil Treatment In A Patient With Autism: A Case Report | 2021 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy | 2021 | Epilepsia | Nível V — Série de Casos | DOI |
White matter integrity after cannabidiol administration for treatment resistant epilepsy | 2021 | Epilepsia | Nível I — RCT | DOI |
Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial | 2021 | Epilepsia | Nível V — Série de Casos | DOI |
Longitudinal impact of cannabidiol on EEG measures in subjects with treatment-resistant epilepsy | 2021 | Epilepsia | Nível II — Coorte | DOI |
Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry | 2021 | Dor Neuropática | Nível IV — Estudos transversais | DOI |
Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients | 2021 | Epilepsia | Nível V — Série de Casos | DOI |
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma | 2021 | Câncer - Glioblastoma | Nível I — RCT | DOI |
A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects | 2021 | Saudável | Nível I — RCT | DOI |
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy | 2021 | Epilepsia | Nível II — Coorte | DOI |
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures | 2021 | Epilepsia | Nível I — RCT | DOI |
Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double-blinded placebo-controlled interventional study | 2021 | Dermatite Atópica | Nível I — RCT | DOI |
Medical cannabis for the treatment of fibromyalgia syndrome: a retrospective, open-label case series | 2021 | Fibromialgia | Nível V — Série de Casos | DOI |
Long Term Safety and Efficacy of Highly Purified Cannabidiol for Treatment Refractory Epilepsy | 2021 | Epilepsia | Nível IV — Estudos transversais | DOI |
Sativex (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience | 2021 | Esclerose Múltipla | Nível III — Caso-Controle | DOI |
Long-term safety and efficacy of add-on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long-term open-label extension trial | 2021 | Epilepsia - Síndrome de Lennox-Gastaut | Nível I — RCT | DOI |
Disposition of Oral Cannabidiol‑Rich Cannabis Extracts in Children with Epilepsy | 2020 | Epilepsia | Nível II — Coorte | DOI |
Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam | 2020 | Epilepsia | Nível III — Caso-Controle | DOI |
Medical cannabis and cognitive performance in middle to old adults treated for chronic pain | 2020 | Dor Crônica | Nível IV — Estudos transversais | DOI |
The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder | 2020 | Transtorno de Estresse Pós-Traumático | Nível II — Coorte | DOI |
Effectiveness of cannabidiol in a prospective cohort of children with drug resistant epileptic encephalopathy in Argentina | 2020 | Epilepsia | Nível II — Coorte | DOI |
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial | 2020 | Epilepsia - Síndrome de Dravet | Nível I — RCT | DOI |
Cannabidiol (CBD) as a treatment of acute and chronic back pain: A case series and literature review | 2020 | Dor Crônica | Nível V — Série de Casos | DOI |
Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial | 2020 | Câncer | Nível I — RCT | DOI |
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial | 2020 | Esclerose Múltipla | Nível I — RCT | DOI |
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis | 2020 | Episódio Psicótico | Nível III — Caso-Controle | DOI |
Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Efects among Palliative Cancer Patients | 2020 | Câncer | Nível IV — Estudos transversais | DOI |
Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis | 2020 | Esclerose Múltipla | Nível III — Caso-Controle | DOI |
Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy | 2020 | Epilepsia | Nível I — RCT | DOI |
Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy | 2020 | Epilepsia | Nível II — Coorte | DOI |
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy | 2020 | Epilepsia | Nível III — Caso-Controle | DOI |
Nabiximols plus robotic assisted gait training in improving motor performances in people with Multiple Sclerosis | 2020 | Esclerose Múltipla | Nível I — RCT | DOI |
The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers | 2020 | Saudável | Nível II — Coorte | DOI |
Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers | 2020 | Saudável | Nível I — RCT | DOI |
A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report | 2020 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
A pilot randomised placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability | 2020 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples | 2020 | Placa Dental | Nível III — Caso-Controle | DOI |
Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy | 2020 | Epilepsia | Nível I — RCT | DOI |
Abrupt withdrawal of cannabidiol (CBD): A randomized trial | 2020 | Saudável | Nível I — RCT | DOI |
Potential anti-inflammatory and antioxidant effects of cannabidiol in bipolar depression | 2020 | Bipolaridade | Nível II — Coorte | DOI |
The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex | 2020 | Epilepsia - Esclerose tuberosa | Nível III — Caso-Controle | DOI |
A Phase I, Open‑Label, Parallel‑Group, Single‑Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment | 2020 | Renais Crônicos | Nível III — Caso-Controle | DOI |
Use of oral cannabis extracts in the pediatric palliative care setting: A retrospective chart review | 2020 | Câncer | Nível IV — Estudos transversais | DOI |
The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study | 2020 | Saudável | Nível I — RCT | DOI |
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study | 2020 | Doença de Parkinson | Nível IV — Estudos transversais | DOI |
The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study | 2020 | Saudável | Nível IV — Estudos transversais | DOI |
Efficacy and Tolerability of a Shampoo Containing Broad-Spectrum Cannabidiol in the Treatment of Scalp Inflammation in Patients with Mild to Moderate Scalp Psoriasis or Seborrheic Dermatitis | 2020 | Psoríase | Nível V — Série de Casos | DOI |
Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy | 2020 | Epilepsia | Nível V — Série de Casos | DOI |
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex A Placebo-Controlled Randomized Clinical Trial | 2020 | Epilepsia - Esclerose tuberosa | Nível I — RCT | DOI |
Individual and combined effects of Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) on 3 striato-cortical connectivity in the human brain | 2020 | Saudável | Nível II — Coorte | DOI |
A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis | 2020 | Episódio Psicótico | Nível III — Caso-Controle | DOI |
Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial | 2020 | Paralisia Cerebral | Nível I — RCT | DOI |
Cannabidiol in treatment of refractory epileptic spasms: An open label study | 2020 | Epilepsia | Nível IV — Estudos transversais | DOI |
Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study | 2020 | Enxaqueca | Nível IV — Estudos transversais | DOI |
Topical cannabis-based medicines – A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: An open label trial | 2020 | Úlceras de Calcifilaxia Não Urêmica | Nível V — Série de Casos | DOI |
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease | 2020 | Doença de Parkinson | Nível I — RCT | DOI |
Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy | 2020 | Epilepsia | Nível III — Caso-Controle | DOI |
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities | 2020 | Dor Neuropática | Nível I — RCT | DOI |
Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | 2020 | Fibromialgia | Nível I — RCT | DOI |
Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial | 2020 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study | 2020 | Epilepsia | Nível II — Coorte | DOI |
Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study | 2019 | Epilepsia - Síndrome de Lennox-Gastaut | Nível II — Coorte | DOI |
A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy | 2019 | Epilepsia | Nível V — Série de Casos | DOI |
Striking lung cancer response to self_x0002_administration of cannabidiol: A case report and literature review | 2019 | Câncer de Pulmão | Nível V — Série de Casos | DOI |
Neurological Improvement with Medical Cannabis in a Progressive Supranuclear Palsy Patient: A Case Report | 2019 | Paralisia Supranuclear Progressiva | Nível V — Série de Casos | DOI |
Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders | 2019 | Ansiedade | Nível II — Coorte | DOI |
Medical cannabis and insomnia in older adults with chronic pain: a cross-sectional study | 2019 | Insônia | Nível IV — Estudos transversais | DOI |
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome | 2019 | Síndrome do X Frágil | Nível V — Série de Casos | DOI |
Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report | 2019 | Neurofibromatose | Nível V — Série de Casos | DOI |
A therapeutic effect of CBD-enriched ointment in inflammatory skin diseases and cutaneous scars | 2019 | Cicatriz | Nível V — Série de Casos | DOI |
Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities | 2019 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial | 2019 | Dependência Química - Heroína | Nível I — RCT | DOI |
Cannabidiol Interacts Significantly with Everolimus—Report of a Patient with Tuberous Sclerosis Complex | 2019 | Epilepsia - Esclerose tuberosa | Nível V — Série de Casos | DOI |
Changes in Cortisol Awakening Response Before and After Development of Posttraumatic Stress Disorder, Which Cannot be Avoided with Use of Cannabidiol: A Case Report | 2019 | Transtorno de Estresse Pós-Traumático | Nível V — Série de Casos | DOI |
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test | 2019 | Saudável | Nível III — Caso-Controle | DOI |
Cannabidiol in Anxiety and Sleep: A Large Case Series | 2019 | Insônia | Nível V — Série de Casos | DOI |
Neuroprotective effects of cannabidiol following concussion: A case study | 2019 | Concussão | Nível V — Série de Casos | DOI |
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results | 2019 | Epilepsia | Nível III — Caso-Controle | DOI |
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series | 2019 | Transtorno de Estresse Pós-Traumático | Nível V — Série de Casos | DOI |
A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment | 2019 | Problema Hepático | Nível III — Caso-Controle | DOI |
Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey | 2019 | Síndrome de Tourette | Nível IV — Estudos transversais | DOI |
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial | 2019 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis | 2019 | Episódio Psicótico | Nível II — Coorte | DOI |
Topical CBD for the Management of Acute and Chronic Pain: A Brief Review and Report of an Open-Label Dose-Ranging Clinical Trial | 2019 | Dor Crônica | Nível V — Série de Casos | DOI |
Cognitive Functioning following Long-term Cannabidiol use in Adults with Treatment Resistant Epilepsy | 2019 | Epilepsia | Nível V — Série de Casos | DOI |
fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy | 2019 | Epilepsia | Nível IV — Estudos transversais | DOI |
Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy | 2019 | Epilepsia | Nível V — Série de Casos | DOI |
Effects of CBD-Enriched Cannabis sativa Extract on Autism Spectrum Disorder Symptoms: An Observational Study of 18 Participants Undergoing Compassionate Use | 2019 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry | 2019 | Dor Crônica | Nível III — Caso-Controle | DOI |
Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program | 2019 | Epilepsia | Nível II — Coorte | DOI |
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD) | 2019 | Esclerose Lateral Amiotrófica | Nível II — Coorte | DOI |
Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial | 2019 | Disfunções Temporomandibulares | Nível I — RCT | DOI |
Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity | 2019 | Saudável | Nível II — Coorte | DOI |
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy | 2019 | Transtorno do Espectro Autista | Nível IV — Estudos transversais | DOI |
A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects | 2019 | Saudável | Nível I — RCT | DOI |
Case Report: Clinical Outcome and Image Response of Two Patients With Secondary High-Grade Glioma Treated With Chemoradiation, PCV, and Cannabidiol | 2019 | Câncer - Glioma | Nível V — Série de Casos | DOI |
Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study | 2019 | Epilepsia | Nível V — Série de Casos | DOI |
Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study | 2019 | Dor Crônica | Nível V — Série de Casos | DOI |
Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients | 2019 | Epilepsia | Nível III — Caso-Controle | DOI |
The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD) | 2019 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol | 2019 | Epilepsia | Nível I — RCT | DOI |
Vaporized Cannabis Is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome | 2019 | Síndrome de Tourette | Nível V — Série de Casos | DOI |
Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study | 2019 | Saudável | Nível I — RCT | DOI |
Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder | 2019 | Transtorno do Espectro Autista | Nível I — RCT | DOI |
Quality of Life in Adults Enrolled in an Open-Label Study of Cannabidiol (CBD) for Treatment-Resistant Epilepsy | 2019 | Epilepsia | Nível IV — Estudos transversais | DOI |
Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal | 2018 | Dependência Química - Nicotina | Nível I — RCT | DOI |
Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results | 2018 | Epilepsia | Nível III — Caso-Controle | DOI |
Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report | 2018 | Síndrome de Tourette | Nível V — Série de Casos | DOI |
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome | 2018 | Epilepsia - Síndrome de Dravet | Nível I — RCT | DOI |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis | 2018 | Colite Ulcerosa | Nível I — RCT | DOI |
Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis A Randomized Clinical Trial | 2018 | Episódio Psicótico | Nível I — RCT | DOI |
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | 2018 | Epilepsia - Síndrome de Lennox-Gastaut | Nível I — RCT | DOI |
Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia | 2018 | Epilepsia | Nível IV — Estudos transversais | DOI |
A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome | 2018 | Epilepsia - Síndrome de Dravet | Nível II — Coorte | DOI |
Medical Cannabis for Adult Attention Deficit Hyperactivity Disorder: Sociological Patient Case Report of Cannabinoid Therapeutics in Finland | 2018 | Transtorno de Déficit de Atenção e Hiperatividade | Nível V — Série de Casos | DOI |
Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain | 2018 | Dor - Câncer | Nível I — RCT | DOI |
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study | 2018 | Epilepsia | Nível IV — Estudos transversais | DOI |
Self-initiated use of topical cannabidiol oil for epidermolysis bullosa | 2018 | Epidermólise Bolhosa | Nível V — Série de Casos | DOI |
The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group | 2018 | Ansiedade | Nível II — Coorte | DOI |
Probing the endocannabinoid system in healthy volunteers: Cannabidiol alters fronto-striatal resting-state connectivity | 2018 | Saudável | Nível II — Coorte | DOI |
Open-label use of Highly purified CBD (Epidiolex) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes | 2018 | Epilepsia - Deficiência de CDKL5, Sindromes de Aicardi, Doose e Dup15q | Nível III — Caso-Controle | DOI |
Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial | 2018 | Epilepsia - Síndrome de Dravet | Nível I — RCT | DOI |
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship | 2018 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems—A Retrospective Feasibility Study | 2018 | Transtorno do Espectro Autista | Nível V — Série de Casos | DOI |
A Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects | 2018 | Saudável | Nível I — RCT | DOI |
The safety of topical cannabidiol (CBD) for the treatment of acne | 2018 | Acne | Nível V — Série de Casos | DOI |
Sativex as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial | 2018 | Esclerose Múltipla | Nível I — RCT | DOI |
Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay | 2018 | Transplante Renal | Nível V — Série de Casos | DOI |
Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial | 2018 | Dependência Química - Maconha THC | Nível IV — Estudos transversais | DOI |
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials | 2018 | Esclerose Múltipla | Nível II — Coorte | DOI |
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings | 2018 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial | 2018 | Esquizofrenia | Nível I — RCT | DOI |
The efects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers | 2018 | Dependência Química - Nicotina | Nível I — RCT | DOI |
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial | 2018 | Epilepsia - Síndrome de Lennox-Gastaut | Nível I — RCT | DOI |
Long‑Term Safety, Tolerability, and Efcacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US | 2018 | Epilepsia | Nível I — RCT | DOI |
Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus | 2018 | Epilepsia | Nível V — Série de Casos | DOI |
Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders | 2018 | Distonia | Nível IV — Estudos transversais | DOI |
Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users | 2018 | Dependência Química - Maconha THC | Nível V — Série de Casos | DOI |
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial | 2018 | Esclerose Lateral Amiotrófica | Nível I — RCT | DOI |
Individual and combined effects of acute Δ-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function | 2018 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study | 2018 | Saudável | Nível I — RCT | DOI |
An interaction between warfarin and cannabidiol, a case report | 2017 | Síndrome de Marfan | Nível V — Série de Casos | DOI |
Cannabidiol in the management of in_x0002_patient cannabis withdrawal: clinical case series | 2017 | Dependência Química - Maconha THC | Nível V — Série de Casos | DOI |
The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy | 2017 | Câncer Cerebral | Nível V — Série de Casos | DOI |
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | 2017 | Epilepsia - Síndrome de Dravet | Nível I — RCT | DOI |
THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study | 2017 | Esclerose Múltipla - Sistema Urinário | Nível IV — Estudos transversais | DOI |
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial | 2017 | Doença de Crohn | Nível I — RCT | DOI |
Topical Medical Cannabis: A New Treatment for Wound PaindThree Cases of Pyoderma Gangrenosum | 2017 | Pyoderma Gangrenosum | Nível V — Série de Casos | DOI |
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial | 2017 | Transtorno de Déficit de Atenção e Hiperatividade | Nível I — RCT | DOI |
Interactions between cannabidiol and commonly used antiepileptic drugs | 2017 | Epilepsia | Nível I — RCT | DOI |
Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome | 2017 | Síndrome de Sturge-Weber | Nível V — Série de Casos | DOI |
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life | 2017 | Saudável | Nível I — RCT | DOI |
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial | 2017 | Esquizofrenia | Nível I — RCT | DOI |
Sativex Oromucosal Spray as Adjunctive Therapy in Advanced Cancer Patients With Chronic Pain Unalleviated by Optimized Opioid Therapy: Two Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies | 2017 | Dor - Câncer | Nível I — RCT | DOI |
Quality of Life of Childhood Epilepsy (QOLCE) in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol (CBD) | 2017 | Epilepsia | Nível II — Coorte | DOI |
Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis | 2016 | Saudável | Nível IV — Estudos transversais | DOI |
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex | 2016 | Epilepsia - Esclerose tuberosa | Nível IV — Estudos transversais | DOI |
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray | 2016 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report | 2016 | Transtorno de Estresse Pós-Traumático | Nível V — Série de Casos | DOI |
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice | 2016 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity | 2016 | Esclerose Múltipla | Nível II — Coorte | DOI |
The Effect of Medicinal Cannabis on Pain and Quality of Life Outcomes in Chronic Pain: a Prospective Open-label Study | 2016 | Dor Crônica | Nível II — Coorte | DOI |
Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases | 2016 | Epilepsia | Nível V — Série de Casos | DOI |
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial | 2016 | Epilepsia | Nível II — Coorte | DOI |
Evaluating Sativex in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis | 2016 | Esclerose Múltipla | Nível III — Caso-Controle | DOI |
Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings | 2016 | Dependência Química - Maconha THC | Nível II — Coorte | DOI |
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease | 2016 | Doença de Huntington | Nível I — RCT | DOI |
Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses | 2016 | Dependência Química - Maconha THC | Nível II — Coorte | DOI |
Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol | 2016 | Epilepsia | Nível V — Série de Casos | DOI |
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study | 2016 | Diabetes Tipo 2 | Nível I — RCT | DOI |
CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience | 2016 | Epilepsia | Nível V — Série de Casos | DOI |
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity | 2016 | Esclerose Múltipla | Nível III — Caso-Controle | DOI |
Pure Cannabidiol in the Treatment of Malignant Migrating Partial Seizures in Infancy: A Case Report | 2015 | Epilepsia | Nível V — Série de Casos | DOI |
Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans | 2015 | Dependência Química - Opióides | Nível I — RCT | DOI |
Cannabinoid Modulation of Functional Connectivity within Regions Processing Attentional Salience | 2015 | Saudável | Nível IV — Estudos transversais | DOI |
Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation | 2015 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Efficacy and safety of nabiximols (Sativex) on multiple sclerosis spasticity in a real-life Italian monocentric study | 2015 | Esclerose Múltipla | Nível II — Coorte | DOI |
Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study | 2015 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content | 2015 | Eritema | Nível I — RCT | DOI |
Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report | 2015 | Dependência Química - Maconha THC | Nível V — Série de Casos | DOI |
Sativex and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis | 2015 | Esclerose Múltipla | Nível I — RCT | DOI |
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy | 2015 | Epilepsia | Nível II — Coorte | DOI |
A Multicentre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Study of Effect of Long-Term Sativex Treatment on Cognition and Mood of Patients with Spasticity Due to Multiple Sclerosis | 2014 | Esclerose Múltipla | Nível I — RCT | DOI |
Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity | 2014 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain | 2014 | Dor Neuropática | Nível III — Caso-Controle | DOI |
Assessing the Neurophysiological Effects of Cannabinoids on Spasticity in Multiple Sclerosis | 2014 | Esclerose Múltipla | Nível I — RCT | DOI |
Nabiximols (THC/CBD Oromucosal Spray, Sativex) in Clinical Practice – Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity | 2014 | Esclerose Múltipla | Nível V — Série de Casos | DOI |
Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series | 2014 | Doença de Parkinson - Sono | Nível V — Série de Casos | DOI |
Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice | 2014 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial | 2014 | Doença de Parkinson | Nível I — RCT | DOI |
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal A Randomized Clinical Trial | 2014 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Opposite effects of THC and CBD on auditory mismatch negativity: a randomised controlled trial of acute cannabinoid | 2014 | Saudável | Nível II — Coorte | DOI |
Cannabidiol enhances consolidation of explicit fear extinction in humans | 2013 | Ansiedade | Nível II — Coorte | DOI |
An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics | 2013 | Dor - Câncer | Nível IV — Estudos transversais | DOI |
A Multiple‐Dose, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray | 2013 | Saudável | Nível II — Coorte | DOI |
A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers | 2013 | Saudável | Nível I — RCT | DOI |
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings | 2013 | Dependência Química - Nicotina | Nível I — RCT | DOI |
Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial | 2012 | Dor - Câncer | Nível I — RCT | DOI |
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report | 2012 | Dependência Química - Maconha THC | Nível V — Série de Casos | DOI |
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols) | 2012 | Esclerose Múltipla | Nível I — RCT | DOI |
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis | 2012 | Esclerose Múltipla | Nível I — RCT | DOI |
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia | 2012 | Esquizofrenia | Nível I — RCT | DOI |
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment | 2012 | Saudável | Nível I — RCT | DOI |
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis | 2012 | Esclerose Múltipla | Nível II — Coorte | DOI |
Modulation of Auditory and Visual Processing by Δ-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study | 2011 | Saudável | Nível I — RCT | DOI |
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects | 2011 | Saudável | Nível IV — Estudos transversais | DOI |
A randomized, double‐blind, placebo‐controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use | 2011 | Dependência Química - Maconha THC | Nível I — RCT | DOI |
Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety | 2011 | Doença Pulmonar Obstrutiva Crônica | Nível IV — Estudos transversais | DOI |
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients | 2011 | Ansiedade | Nível II — Coorte | DOI |
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report | 2011 | Ansiedade | Nível II — Coorte | DOI |
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis | 2010 | Esclerose Múltipla - Sistema Urinário | Nível II — Coorte | DOI |
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study | 2010 | Dependência Química - Maconha THC | Nível II — Coorte | DOI |
Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology | 2010 | Saudável | Nível I — RCT | DOI |
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain | 2010 | Dor - Câncer | Nível I — RCT | DOI |
A double-blind, randomized, placebo_x0002_controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis | 2010 | Esclerose Múltipla | Nível I — RCT | DOI |
Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis | 2010 | Dependência Química - Maconha THC | Nível IV — Estudos transversais | DOI |
Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol | 2010 | Saudável | Nível I — RCT | DOI |
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain | 2010 | Dor - Câncer | Nível I — RCT | DOI |
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD) | 2010 | Esquizofrenia | Nível II — Coorte | DOI |
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis | 2010 | Esclerose Múltipla | Nível I — RCT | DOI |
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing | 2009 | Saudável | Nível I — RCT | DOI |
Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study | 2009 | Esclerose Múltipla | Nível I — RCT | DOI |
Cannabidiol for the treatment of psychosis in Parkinson's disease | 2008 | Doença de Parkinson | Nível III — Caso-Controle | DOI |
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition | 2008 | Saudável | Nível I — RCT | DOI |
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis | 2008 | Esquizofrenia | Nível IV — Estudos transversais | DOI |
Cannabinoid-induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis | 2008 | Esclerose Múltipla | Nível I — RCT | DOI |
Oromucosal Δ9-Tetrahydrocannabinol/Cannabidiol for Neuropathic Pain Associated with Multiple Sclerosis: An Uncontrolled, Open-Label, 2-Year Extension Trial | 2007 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial | 2007 | Dor Neuropática | Nível I — RCT | DOI |
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis | 2007 | Esclerose Múltipla | Nível I — RCT | DOI |
Cannabidiol monotherapy for treatment-resistant schizophrenia | 2006 | Esquizofrenia | Nível V — Série de Casos | DOI |
A multicenter Dose-escalation Study of the Analgesic and Adverse Effects of an Oral Cannabis Extract (Cannador) for Postoperative Pain Management | 2006 | Dor Pós Cirúrgica | Nível II — Coorte | DOI |
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis | 2006 | Esclerose Múltipla | Nível IV — Estudos transversais | DOI |
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis | 2006 | Artrite Reumatóide | Nível I — RCT | DOI |
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up | 2005 | Esclerose Múltipla | Nível I — RCT | DOI |
Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of Δ9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract | 2005 | Saudável | Nível I — RCT | DOI |
Randomized, controlled trial of cannabis based medicine in central pain in multiple sclerosis | 2005 | Esclerose Múltipla | Nível I — RCT | DOI |
Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow | 2004 | Saudável | Nível II — Coorte | DOI |
An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis | 2004 | Esclerose Múltipla | Nível V — Série de Casos | DOI |
Cannabis for dyskinesia in Parkinson disease: A randomized double-blind crossover study | 2004 | Doença de Parkinson | Nível I — RCT | DOI |
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients | 2004 | Esclerose Múltipla | Nível I — RCT | DOI |
Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults | 2004 | Saudável - Sono | Nível I — RCT | DOI |
Efficacy, safety and torelability of an orally administered cannabis extract in the treatment of spasticity in patiets with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study | 2004 | Esclerose Múltipla | Nível I — RCT | DOI |
Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial | 2003 | Dor Neuropática | Nível II — Coorte | DOI |
Safety, tolerability, and efficacy of orally administered cannabinoids in MS | 2002 | Esclerose Múltipla | Nível I — RCT | DOI |
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms | 2002 | Esclerose Múltipla, Lesão da medula espinhal, Lesão do plexo braquial e amputação de membros por neurofibromatose | Nível IV — Estudos transversais | DOI |
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man | 1999 | Saudável | Nível III — Caso-Controle | DOI |
Effects of ipsapirone and cannabidiol on human experimental anxiety | 1993 | Ansiedade | Nível III — Caso-Controle | DOI |
Controlled Clinical Trial of Cannabidiol in Huntington's Disease | 1991 | Doença de Huntington | Nível I — RCT | DOI |
Open Label Evaluation Of Cannabidiol In Dystonic Movement Disorders | 1986 | Distonia | Nível V — Série de Casos | DOI |
Cannabidiol in Dystonic Movement Disorders | 1985 | Distonia | Nível V — Série de Casos | DOI |
Action of Cannabidiol on the Anxiety and Other Effects Produced by Δ9-THC in Normal Subjects | 1982 | Saudável | Nível III — Caso-Controle | DOI |
Chronic Administration of Cannabidiol to Healthy Volunteers and Epiletic patients | 1980 | Epilepsia | Nível IV — Estudos transversais | DOI |
Interaction of Cannabidiol and Alcohol in Humans | 1979 | Dependência Química - Alcool | Nível I — RCT | DOI |
Influence of cannabidiol on delta-9-tetrahydrocannabinol effects | 1976 | Saudável | Nível I — RCT | DOI |
Cannabidiol Interferes With The Effects Of Δ9-Tetrahydrocannabinol In Man | 1974 | Saudável | Nível IV — Estudos transversais | DOI |
Cannabidiol and Cannabinol in Man | 1973 | Saudável | Nível IV — Estudos transversais | DOI |
A Comparison of the Pharmacological Activity in Man of Intravenously Administered Δ9-Tetrahydrocannabinol, Cannabinol, and Cannabidiol | 1973 | Saudável | Nível IV — Estudos transversais | DOI |